59 Results

People

  1. DeMatteo
    DeMatteo
  2. Aghajanian
    Aghajanian
  3. Antonescu
    Antonescu
  4. Bosl
    Bosl
  5. Gonen
    Gonen
  6. Hudis
    Hudis
  7. Kris
    Kris
  8. Krug
    Krug
  9. Levine
    Levine
  10. Miller
    Miller

Groups

  1. Department of Medicine (34)
  2. Solid Tumor Oncology Division (24)
  3. Hematologic Malignancies, Division of (13)
  4. GSK Faculty (11)
  5. Surgery (10)
  6. Center for Hematologic Malignancies (8)
  7. Gynecologic Medicine Service (8)
  8. Survivorship Research (7)
  9. GDMT, Medicine (6)
  10. Gynecology Disease Management Team (6)
  1. "cancer resistance"
  2. "Elsevier Inc."
Formats
  1. Journal Article (55)
  2. Review (3)
  3. Editorial (1)
Groups
  1. Department of Medicine (34)
  2. Solid Tumor Oncology Division (24)
  3. Hematologic Malignancies, Division of (13)
  4. GSK Faculty (11)
  5. Surgery (10)
  6. Center for Hematologic Malignancies (8)

More Groups

People
  1. Ronald DeMatteo (5)
  2. Carol Aghajanian (2)
  3. Clifford Hudis (2)
  4. Cristina Antonescu (2)
  5. David Spriggs (2)
  6. Douglas Levine (2)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (3)
  4. 2020 (2)
  5. 2019 (1)
  6. 2018 (4)

More Years

Publications
  1. Gynecologic Oncology (8)
  2. Seminars in Oncology (7)
  3. Journal of Thoracic Oncology (5)
  4. Surgical Oncology Clinics of North America (5)
  5. Hematology/Oncology Clinics of North America (4)
  6. Cancer Treatment Reviews (3)

More Publications

Publishers
  1. Elsevier Inc. (59)

Results (59)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MYB alternative promoter activity is increased in adenoid cystic carcinoma metastases and is associated with a specific gene expression signature
    Journal Article

    Huang, J.; Fehr, A.; Jäwert, F.; Nilsson, J. A.; Morris, L. G. T.; Stenman, G.; Andersson, M. K.
    Oral Oncology (2024)

    Fulltext@MSK | Save
  • Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
    Review

    Jhaveri, K.; Marmé, F.
    Cancer Treatment Reviews (2024)

    Fulltext@MSK | Save
  • Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: Results of a phase II study (MOONSTONE/GOG-3032)
    Journal Article

    Randall, L. M.; O'Malley, D. M.; Monk, B. J.; Coleman, R. L.; Gaillard, S.; Adams, S.; Duska, L. R.; Dalton, H.; Holloway, R. W.; Huang, M.; more...
    Gynecologic Oncology (2023)

    Fulltext@MSK | Save
  • Future directions in the frontline management of Waldenström macroglobulinemia
    Review

    Buske, C.; Palomba, M. L.
    Hematology/Oncology Clinics of North America (2023)

    Fulltext@MSK | Save
  • Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer
    Review

    Rubinstein, M.; Shen, S.; Monk, B. J.; Tan, D. S. P.; Nogueira-Rodrigues, A.; Aoki, D.; Sehouli, J.; Makker, V.
    Gynecologic Oncology (2022)

    Fulltext@MSK | Save
  • High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy
    Journal Article

    Dercle, L.; Ammari, S.; Roblin, E.; Bigorgne, A.; Champiat, S.; Taihi, L.; Plaian, A.; Hans, S.; Lakiss, S.; Tselikas, L.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma
    Editorial

    Holstein, S. A.; Asimakopoulos, F.; Azab, A. K.; Bianchi, G.; Bhutani, M.; Crews, L. A.; Cupedo, T.; Giles, H.; Gooding, S.; Hillengass, J.; more...
    Transplantation and Cellular Therapy (2022)

    Fulltext@MSK | Save
  • Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study
    Journal Article

    Hamilton, E.; O'Malley, D. M.; O'Cearbhaill, R.; Cristea, M.; Fleming, G. F.; Tariq, B.; Fong, A.; French, D.; Rossi, M.; Brickman, D.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies
    Journal Article

    Solomon, B. J.; Tan, L.; Lin, J. J.; Wong, S. Q.; Hollizeck, S.; Ebata, K.; Tuch, B. B.; Yoda, S.; Gainor, J. F.; Sequist, L. V.; more...
    Journal of Thoracic Oncology (2020)

    Fulltext@MSK | Save
  • Inotuzumab ozogamicin as chemotherapy-sparing salvage in a 67-year-old man with primary refractory B-cell acute lymphoblastic leukemia with high-risk genomic features
    Journal Article

    Yang, X.; Sen, F.; Geyer, M. B.
    Leukemia Research Reports (2019)

    Fulltext@MSK | Save